MedAccess’ cover photo
MedAccess

MedAccess

Public Health

Accelerating access to medical innovations

About us

We are a social enterprise committed to improving health in more than 110 countries. Our mission is to cut illness and death by speeding up access to lifesaving vaccines, medicines, diagnostics and technologies for people in underserved communities. Using $200 million capital from British International Investment, our agile team of global health and investment experts shapes agreements that break down the barriers preventing people from accessing medical innovations. We are independent and not-for-profit, with any operating surpluses invested into developing new agreements to accelerate access to healthcare.

Website
https://medaccess.org/
Industry
Public Health
Company size
11-50 employees
Headquarters
London
Type
Nonprofit
Founded
2017
Specialties
global health, public health, business analysis, innovative finance, financial guarantees, and international development

Locations

Employees at MedAccess

Updates

  • 📩 The latest Access Matters newsletter is out now! This edition includes:   🔷 Our partnership with European Investment Bank (EIB) to boost access to essential medical supplies in Africa 🔷 Our partnership with Clinton Health Access Initiative, Inc. (supported by the Wellcome Trust) to make mental health treatments more accessible and affordable 🔷 New Market Shapers interviews with Hema Srinivasan, Achim Reddig and Michael Anderson CB 🔷 The Global Fund's replenishment 🔷 A new World Health Organization report outlining a vision for equitable access to novel TB vaccines + more   You can read it here ⬇️

  • View organization page for MedAccess

    7,094 followers

    🌟 MARKET SHAPERS: THREE NEW INTERVIEWS LIVE! 🌟 We’re delighted to share three new episodes of Market Shapers, our interview series that explores the science, art and impact of market shaping. In the latest interviews, MedAccess CEO Michael Anderson CB talks to co-founder of Crowdcure and former Chief Access Officer at MedAccess, Hema Srinivasan, and Director Global Public Health at BASF, Achim Reddig before the tables are turned, and Andrew Jack puts Michael in the hot seat. The series brings together some of the most influential voices in global health to explore how market shaping works, why it matters and where it’s heading. In these new instalments: 🦟 Achim discusses the onward chain of innovation that followed from a MedAccess volume guarantee for the Interceptor® G2 mosquito net ❤️ Hema explains why passion is at the heart of all effective market shaping and looks at where the discipline might go next 💡 Michael unpacks the art of negotiating volume guarantees and outlines why he thinks the future looks bright for market shaping 🎥 Watch the series here: https://lnkd.in/eQfPEkZA #InnovativeFinance | #HealthForAll | #GlobalHealth

    • No alternative text description for this image
  • Aurélia Nguyen helped to coin the phrase ‘market shaping’ and made the discipline the north star for her career. From COVAX to Gavi, the Vaccine Alliance to CEPI (Coalition for Epidemic Preparedness Innovations) her work has helped to immunise hundreds of millions of children by aligning public health goals with market incentives. In our latest interview with market shaping leaders and visionaries, MedAccess CEO Michael Anderson CB speaks with Aurélia about: 💡 The evolution of market shaping and her experience of helping to build the discipline 📈 What it means for a market to be ‘healthy’ and her favourite example of a market shaping intervention ❤️ The ‘head and heart’ motivations that guide her career 🎥Watch the full interview here: https://lnkd.in/ePkvgB43

    • No alternative text description for this image
  • View organization page for MedAccess

    7,094 followers

    🌟 Market Shapers: Aurélia Nguyen🌟 Aurélia Nguyen has been at the heart of global vaccine access for over two decades. From shaping pricing policy at GSK to leading COVAX at Gavi, the Vaccine Alliance and now serving as Deputy CEO at CEPI (Coalition for Epidemic Preparedness Innovations), she has helped build markets that deliver vaccines widely and equitably. In our latest interview with some of the most influential voices in global health, Aurélia joins MedAccess CEO Michael Anderson CB Anderson and discusses: 💡Her work to define the concept of market shaping and the impact of well-placed market shaping interventions 💉Getting a COVID-19 vaccine to market for low- and middle-income countries and the responsibility she felt to get it right ⭐Why market shaping became the north star for her career 🎥Watch the full interview here: https://lnkd.in/ePkvgB43

  • 📢 Call for Expressions of Interest: UNIMMAP MMS ***Update: Submission deadline extended to 21st November 2025*** We are exploring ways to support regional and local manufacturing of United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) Multiple Micronutrient Supplements (MMS) in low- and middle-income countries. We invite interested manufacturers to submit an Expression of Interest for innovative financing support, such as volume guarantees, aimed at improving access to UNIMMAP MMS. 📅 The deadline for submissions is 21st November 2025. 🔗 https://lnkd.in/eAh7ACeD

    • No alternative text description for this image
  • View organization page for MedAccess

    7,094 followers

    How and why market shaping works is often complex and misunderstood. To shed light on the discipline, we've spoken to influential voices in market shaping and global health to understand how their work has enabled health products to reach the people who need them. In our latest episode, MedAccess CEO Michael Anderson CB and the Gates Foundation’s Natalie Revelle discuss: 🐣 How volume guarantees work in practice and their ability to break the ‘chicken and egg’ dynamic between volume and price 💉 Key agreements Natalie has worked on – from bed nets to contraceptive implants, antiretroviral drugs to COVID-19 rapid tests ❤️ Natalie's love of problem solving and what motivates her to work in innovative financing for health 🎥 Watch the full interview here: https://lnkd.in/emDCidKq #InnovativeFinance | #GlobalHealth | #HealthForAll

    • No alternative text description for this image
  • The world is making progress against tuberculosis – but we still have a long way to go.   The World Health Organization’s Global Tuberculosis Report 2025 shows that, despite a reduction in the number of deaths from TB in 2024, 1.2 million people still died from an illness that is both preventable and treatable.   Access to treatment for drug-resistant tuberculosis (DR-TB) is improving. More than 34,000 people with DR-TB started treatment in 2024 with newer, more effective six-month regimens. Treatment success rates for DR-TB are now above 70%, compared to 50% in 2012.   The report also notes the urgent need for new TB vaccines. With six candidate vaccines in phase III trials, the world is edging closer to a new tool that could significantly reduce the burden of TB for people, communities and countries. MedAccess is pleased to be part of the Finance and Access Working Group, a subsidiary of the WHO TB Accelerator Council, which is focused on ensuring future TB vaccines reach the people who need them as quickly as possible. 🔗 Full report here: https://lnkd.in/eajhi9Xi

    View organization page for World Health Organization

    6,154,747 followers

    #Tuberculosis (TB) is preventable and curable. Yet, it remains one of the world’s deadliest infectious killers, claiming 1.23 million lives in 2024. The WHO Global Tuberculosis Report 2025 talks about the gains made so far and the challenges ahead due to severe funding cuts: https://bit.ly/4qT5ihk

    • Image of a patient in the x-ray laboratory in the background. Text reads 'Tuberculosis is the world's top infectious killer. TB caused 1.23 million deaths in 2024. Ending TB is possible. Fund it, research it, commit to it.'
  • View organization page for MedAccess

    7,094 followers

    📣 NEW PROGRAMME TO EXPLORE MARKET SHAPING SOLUTIONS FOR MENTAL HEALTH CONDITIONS Today, MedAccess announced a new programme to explore market shaping solutions to make treatments for mental health conditions more accessible and affordable in low- and middle-income countries. Funded by a grant from Wellcome Trust and working with the Clinton Health Access Initiative, Inc., the programme will: 🌍Convene global experts and people with lived experience to identify practical treatment options for low-resource settings 🔍 Investigate barriers such as pricing, policies and supply challenges 💡 Develop strategies – including innovative tools like volume guarantees – to improve access Starting with schizophrenia in 2026, MedAccess will identify a shortlist of opportunities where market shaping tools could increase access to treatments for schizophrenia, depression, anxiety and bipolar disorder. Read more about today’s announcement: https://lnkd.in/ec_RekmR #MentalHealth | #GlobalHealth | #HealthForAll

    • No alternative text description for this image
  • View organization page for MedAccess

    7,094 followers

    🌟 Market Shapers: Natalie Revelle 🌟 Natalie Revelle is a global health finance trailblazer. As Director, Volume Guarantees and Senior Financial Adviser at the Gates Foundation, she has led groundbreaking investments that have saved over $1 billion in procurement costs. From vaccines to HIV treatments, Natalie’s financial ingenuity has expanded access to life-saving products in low- and middle-income countries, proving that smart, structured finance can shape markets and deliver impact at scale. In our latest interview with market shaping leaders and visionaries, Natalie joins MedAccess CEO Michael Anderson CB and discusses: 💡Her love of problem solving and how it’s shaped her career 🤝 Why a partnership mentality – rather than an “us versus them” approach – is critical to successful volume guarantees 🛑 The three biggest criticisms levelled at volume guarantees 🎥 Watch the full interview here: https://lnkd.in/em_zgriD #InnovativeFinance | #GlobalHealth | #HealthForAll

Similar pages

Browse jobs

Funding

MedAccess 1 total round

Last Round

Series unknown

US$ 200.0M

See more info on crunchbase